Literature DB >> 6173399

Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

M Schapira, C F Scott, R W Colman.   

Abstract

Although Cl-inhibitor (Cl-INH) and alpha(2)-macroglobulin (alpha(2)M) have been reported as the major inhibitors of plasma kallikrein in normal plasma, there is little quantitative support for this conclusion. Thus, we studied the inactivation of purified kallikrein in normal plasma, as well as in plasma congenitally deficient in Cl-INH, or artificially depleted of alpha(2)M by chemical modification of the inhibitor with methylamine. Under pseudo-first-order conditions, the inactivation rate constant of kallikrein in normal plasma was 0.60 min(-1). This rate constant was reduced to 0.35, 0.30, and 0.06 min(-1), in plasma deficient respectively in Cl-INH, alpha(2)M, or both inhibitors. Thus Cl-INH (42%) and alpha(2)M (50%) were found to be the major inhibitors of kallikrein in normal plasma. Moreover all the other protease inhibitors present in normal plasma contributed only for 8% to the inactivation of the enzyme. To confirm these kinetic results, (125)I-kallikrein (M(r) 85,000) was completely inactivated by various plasma samples, and the resulting mixtures were analyzed by gel filtration on Sepharose 6B CL for the appearance of (125)I-kallikrein-inhibitor complexes. After inactivation by normal plasma, 52% of the active enzyme were found to form a complex (M(r) 370,000) with Cl-INH, while 48% formed a complex (M(r) 850,000) with alpha(2)M. After inactivation by Cl-INH-deficient plasma, >90% of the active (125)I-kallikrein was associated with alpha(2)M. A similar proportion of the label was associated with Cl-INH in plasma deficient in alpha(2)M. After inactivation by plasma deficient in both Cl-INH and alpha(2)M, (125)I-kallikrein was found to form a complex of M(r) 185,000. This latter complex, which may involve antithrombin III, alpha(1)-protease inhibitor, and/or alpha(1)-plasmin inhibitor, was not detectable in appreciable concentrations in the presence of either Cl-INH or alpha(2)M, even after the addition of heparin (2 U/ml). These observations demonstrate that Cl-INH and alpha(2)M are the only significant inhibitors of kallikrein in normal plasma confirming previous predictions based on experiments in purified systems. Moreover, in the absence of either Cl-INH or alpha(2)M, the inactivation of kallikrein becomes almost entirely dependent on the other major inhibitor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173399      PMCID: PMC370996          DOI: 10.1172/jci110470

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

2.  The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states.

Authors:  R W Colman; J W Mason; S Sherry
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

3.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

4.  Determination of trypsin and chymotrypsin with remazolbrilliant blue-hide.

Authors:  H Rinderknecht; P Silverman; M C Geokas; B J Haverback
Journal:  Clin Chim Acta       Date:  1970-05       Impact factor: 3.786

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

7.  The determination of the concentration of hydrolytic enzyme solutions: alpha-chymotrypsin, trypsin, papain, elastase, subtilisin, and acetylcholinesterase.

Authors:  M L Bender; M L Begué-Cantón; R L Blakeley; L J Brubacher; J Feder; C R Gunter; F J Kézdy; J V Killheffer; T H Marshall; C G Miller; R W Roeske; J K Stoops
Journal:  J Am Chem Soc       Date:  1966-12-20       Impact factor: 15.419

8.  Inhibitors of kallikrein in human plasma.

Authors:  D J McConnell
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

9.  Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  44 in total

1.  Deep Intronic Mutation in SERPING1 Caused Hereditary Angioedema Through Pseudoexon Activation.

Authors:  Pavla Hujová; Přemysl Souček; Lucie Grodecká; Hana Grombiříková; Barbora Ravčuková; Pavel Kuklínek; Roman Hakl; Jiří Litzman; Tomáš Freiberger
Journal:  J Clin Immunol       Date:  2020-01-25       Impact factor: 8.317

Review 2.  Proteolytic Systems in Milk: Perspectives on the Evolutionary Function within the Mammary Gland and the Infant.

Authors:  David C Dallas; Niamh M Murray; Junai Gan
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-16       Impact factor: 2.673

Review 3.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Knockdown of circulating C1 inhibitor induces neurovascular impairment, glial cell activation, neuroinflammation, and behavioral deficits.

Authors:  Dorit Farfara; Emily Feierman; Allison Richards; Alexey S Revenko; Robert A MacLeod; Erin H Norris; Sidney Strickland
Journal:  Glia       Date:  2019-03-18       Impact factor: 7.452

5.  Analysis of Milk from Mothers Who Delivered Prematurely Reveals Few Changes in Proteases and Protease Inhibitors across Gestational Age at Birth and Infant Postnatal Age.

Authors:  Veronique Demers-Mathieu; Søren Drud Nielsen; Mark A Underwood; Robyn Borghese; David C Dallas
Journal:  J Nutr       Date:  2017-04-19       Impact factor: 4.798

6.  Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis.

Authors:  H Yamaguchi; H Weidenbach; H Lührs; M M Lerch; G Dickneite; G Adler
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

7.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

8.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation.

Authors:  W Nürnberger; I Michelmann; K Petrik; S Holthausen; R Willers; G Lauermann; B Eisele; U Delvos; S Burdach; U Göbel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

10.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.